NIH

Agilis Biotherapeutics expands Commercial, Medical Teams

Tuesday, May 9, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as chief commercial officer; Kirsten Gruis, M.D., as chief medical officer; and Anne Marie Conway, M.H.A, R.N., as vice president, Clinical Operations.

[Read More]

Patient advocacy in clinical research

Monday, May 1, 2017

The Pulse on Global Trials by Matthew Howes

Earlier this year, the FDA approved the first artificial pancreas for type 1 diabetes. The advancement is remarkable not just for the technology alone, but for how it came to be.

[Read More]

NIH funds seven international centers of excellence for Malaria research

Monday, April 24, 2017

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, announced approximately $9 million in first-year funding, subject to availability, for seven malaria research centers around the world. The seven-year awards continue NIAID’s 2010 program that created the International Centers of Excellence for Malaria Research (ICEMRs) in regions where malaria is endemic. The awards fund three new and four existing centers that work in 14 countries in Africa, Asia and Latin America.

[Read More]

Shirley Ryan AbilityLab launches to move scientific research from bench to bedside

Monday, April 17, 2017

The Rehabilitation Institute of Chicago (RIC) has moved into a new research hospital facility and renamed itself the Shirley Ryan AbilityLab. The former RIC now occupies a $550 million, 1.2 million square foot facility located on prime real estate in downtown Chicago. The AbilityLab aims to create a setting in which research scientists, engineers and other specialists can work side-by-side with clinicians and patients to improve treatment. This approach is a departure from traditional methods of organizing clinical practice and research, and will serve as an experimental model for medical institutions to observe.

[Read More]